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The effector cell mechanisms involved in allograft or tumor rejection are still
controversial (1) . Sprent et al . (2) recently demonstrated that injection of Lyt-2'
cells (positively purified by thepanning method) into adult, thymectomized, bone
marrow-reconstituted (ATXBM)' B6 mice resulted in rejection of skin from the
H-2Kb mutant strain ofB6.C-H-2bm' (bmI), but not the H-21Ab mutant strain of
B6 .C-H-2bm'2 (bm12), whereas injection of L3T4' cells into these mice resulted
in rejection of skin from bm 12, but not bm 1 mice . Similarly, Rosenberg et al .
(3) reported that bmI skin grafts were rejected by B10 nude mice reconstituted
with B6 spleen cells depleted ofL3T4 cells, but not of Lyt-2' cells by pretreat-
ment with mAb and complement. These studies suggested that the rejections of
skin grafts differing at H-2 class I and class II loci are mediated by Lyt-2' and
L3T4' T cells, respectively . Although there have been several studies on B6 H-
2b mutant strains by investigating the immune responsiveness ofB6 mice against
them, there have been few on the cellular mechanisms of the immune responses
against allelic MHC class I or II antigens .
Previously, we and others demonstrated that injections of anti-Lyt-2 and anti-
L3T4 mAb into mice caused selective depletions of Lyt-2' and L3T4+ cells,
respectively (4-7) . In this study we investigated the effect of in vivo administra-
tion of anti-Lyt-2 .2 mAb, anti-L3T4 mAb, or both to recipient mice on skin
graft survival and found that, besides Lyt-2' effector cells, L3T4' cells can also
mediate skin graft rejection with allelic H-2 class I differences in two different
ways, depending on the strain combination .
Materials and Methods
Mice.
￿
The strains of mice used and their respective genotypes are listed in Table I .
C57BL/6 (B6), B10.BR, and B10.A mice were purchased from Shizuoka Laboratory
Animal Center (Shizuoka, Japan) . B6 .C-H-2bm' (bm1) and B6.C-H-26m'2(bm12) mice were
purchased from The Jackson Laboratory (Bar Harbor, ME) . B10.A(2R), B10.AKM, and
B10.AQR mice were provided by Dr . K . Moriwaki, National Institute of Genetics
(Mishima, Japan) . These mice were bred in our colony .
'Abbreviation used in this paper:
￿
ATXBM, adult, thymectomized, bone marrow-reconstituted
mice .
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TABLE I
H-2 Haplotypes ofMouse Strains Used in This Study
Monoclonal Antibodies.
￿
Anti-L3T4 mAb, a rat antibody of the IgG2b immunoglobulin
class, produced by hybridoma GK 1 .5 (8, 9), was kindly provided by Dr. F. Fitch, University
of Chicago (Chicago, IL). Anti-Lyt-2.2 mAb and other mAb used have been described
previously (4). The titers of both anti-L3T4 and anti-Lyt-2 mAb determined by antibody-
mediated complement-dependent cytotoxicity assay were 1 :20,000. These antibodies were
used in the form of ascites from hybridoma bearing mice. The concentrations of anti-
L3T4 and anti-Lyt-2 .2 mAb in pooled ascites were 2.8 and 7.1 mg/ml, respectively, as
quantified by protein assay (Bio-Rad Laboratories, Richmond, CA), and by quantitative
cellulose acetate electrophoresis.
Antibody Administration.
￿
Mice were anesthetized with ether and 0.2 ml of antibodies
(ascites), diluted 1:8 with MEM, was injected through the retrobulbar venous plexus.
Skin Grafting.
￿
Full-thickness skin (0.8-1 .2-cm-diam) from the back of a donor mouse
was grafted onto the side of the thorax of a recipient mouse by suturing it in place with
nylon string (Nichou Co., Tokyo, Japan). The graft was covered with gauze and a plaster
cast for 6 d and then examined daily to score the percentage of complete rejection .
Statistical analyses were done by Student's t test.
Antibody-mediated Complement-dependent Cytotozicity. The procedure used has been
described (10). Preselected rabbit serum was used as complement.
Protein A Assay.
￿
The method has been described (11).
Results
Estimation ofLyt-2+ and L3T' T Cells in Lymph Nodes ofMice Treated with Anti-
Lyt-2.2 or Anti-L3T4 mAb. Clearance of anti-Lyt-2 .2 and anti-L3T4 mAb in
mice was studied by the cytotoxic test with B6 thymocytes as target cells, using
serum specimens obtained every other day after in vivo administration of mAb.
The antibody titer gradually decreased, and disappeared by day 13-15 after
treatment with anti-Lyt-2.2 mAb, and by day 7 after treatment with anti-L3T4
mAb. Because of its rather rapid clearance, anti-L3T4 mAb was injected on day
14 as well as on days 0 and 4, on which days anti-Lyt-2.2 mAb was injected.
Changes in the number of Lyt-2+ and L3T4' T cells in the lymph nodes with
time were estimated. As shown in Fig. 1, suppression ofLyt-2+ cells were observed
until about day 50 after injection of anti-Lyt-2 .2 mAb, whereas suppression of
L3T4+ cells was observed until about day 30 after injection of anti-L3T4 mAb.
Results in strains B6, B10.A, B10 .AKM, B10.BR, and B10.A(2R) were not
significantly different.
Effect of In Vivo Administration of Anti-Lyt-2.2 mAb on Skin Graft Rejection with
Allelic H-2 Class I Difference.
￿
The effect of in vivo administration of anti-Lyt-
Strain
H-2 haplo-
type K
H-2
A
regions
E S D
C57BL/6 (B6) b b b b b b
B6.C-H-2bm' (bml) bm1 bm 1 b b b b
B6.C-H-2bm'2 (bm12) bm12 b bm12 b b b
B10.BR k k k k k k
B10.A a k k k d d
B10.A(2R) h2 k k k d b
B10.AKM m k k k k q
B10.AQR yI q k k d d984
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FIGURE 1 .
￿
The phenotype of lymph node
cells from B6 mice that were injected (closed
symbols) or not injected (open symbols) with
anti-Lyt-2.2 mAb(A)on days 0 and 4or anti-
L3T4 mAb (B) on days 0, 4, and 14 was
determined kinetically with Thy-1.2 (O),
L3T4 (A), or Lyt-2.2 (O) by antibody-medi-
ated complement-dependent cytotoxicity as-
say. O; Background lysis. Tests were done in
quadruplicate.
2.2 mAb on skin graft rejection was investigated with combinations of allelic H-
2 class I difference using 1310 H-2-congeneic strains. Donor skin was grafted
onto the side of the thorax of recipient mice, and anti-Lyt-2.2 mAb was admin-
istered intravenously on days 0 and 4 after grafting. As shown in Fig. 2, the
administration of anti-Lyt-2.2 mAb significantly prolonged graft survival in all
three combinations when B10.A or B10.AKM was used as recipient, and in the
combination B10.A(2R) --+ B10.BR. However, it did not prolong graft survival
in two other combinations with B10.BR as recipient, or in all three combinations
with BIO.A(2R) as recipient, or in the reciprocal combinations of B10.AQR and
B10.A . Injection of MEM as a control did not significantly affect graft survival
with any combination tested. To determine whether the absence of effect of
anti-Lyt-2.2 mAb in prolonging graft survival was due to injection of insufficient
antibody .and whether the effect of anti-Lyt-2.2 mAb could be enhanced by
increasing the amount ofantibody, we tested the effect on graft survival of three
to five injections of anti-Lyt-2.2 mAb instead of two injections. However, these
additional injections did not result in more or longer graft survival (Table II).
Effect ofIn Vivo Administration ofAnti-L3T4 mAb Alone or With Anti-Lyt-2.2 mAb
on Skin Graft Rejection with Allelic H-2 Class I Differences. To determine whether
L3T4' cells were involved in skin graft rejection with an allelic H-2 class I
difference, we then tested the effect of administration of anti-L3T4 mAb alone
or with anti-Lyt-2.2 mAb on graft rejection with several combinations selected
randomly from among those in which anti-Lyt-2.2 mAb prolonged graft survival
and in which it had no effect. Combinations of B6 and bm 1 or bm12 mutant
strains were also included. As shown in Fig. 3, the administration of anti-L3T4
mAb prolonged survival of skin grafts from bm 12 but not bm 1, and administra-
tion of anti-Lyt-2.2 mAb prolonged survival of skin grafts from bm l but not
bm 12. These results are consistent with previous findings (2, 3) that bm 1 skin
was rejected by Lyt-2+ cells but not L3T4+ cells, and bm12 skin was rejected by
L3T4+ cells but not Lyt-2' cells that were adoptively transferred to ATXBM or
athymic mice. With the allelic H-2 class I difference, the administration of anti-
L3T4 mAb alone did not prolong graft survival of any combination tested.
Whereas anti-L3T4 plus anti-Lyt-2.2 mAb markedly prolonged graft survival in
combinations in which anti-Lyt-2.2 mAb did not prolong graft survival, and
enhanced the effect of anti-Lyt-2.2 mAb in combinations in which anti-Lyt-2.2donor " recipient antigenic
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FIGURE 2.
￿
Effect of in vivo administration of anti-Lyt-2 .2 mAb on skin graft survival and
the production of H-2 antibody in recipient mice in combinations with H-2 class I differences .
Each dot represents the value for an individual mouse . Anti-Lyt-2.2 mAb (closed symbols) or
MEM (control) (open symbols) was injected into recipient mice on days0and 4 after grafting .
A positive effect on graft survival was defined as >50% increase in the mean graft survival
time over that in control mice . A, strain combinations in which anti-Lyt-2 .2 mAbhada positive
effect on graft survival ; B, combinations in which anti-Lyt-2 .2 mAb did not have a positive
effect.The titerof H-2antibody (at a dilution giving 50%rosette-forming cells) wasdetermined
by proteinA assayon serum collected on day 21 after grafting. Spleen cells from donor mice
that had been passed through n~lon wool column were used as target cells. Cells from B6-
Lyt-2.1,3.1 (H-26), CBA/N (H-2 ), or DBA/2 (H-2°) were also used as targets, dependingon
thedonorH-2 antigen to confirm that anti-Lyt-2 .2mAbhas not been detected in mice treated
with the antibody.
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TABLE II
Comparison of the Effect of Two and Three to Five Injections ofLyt-2.2 mAb
in Prolonging GraftSurvival
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FIGURE 3.
￿
Effectsof in vivo administration of anti-L3T4 mAbalone (A) or with anti-Lyt-2.2
mAb (") on skin graft survival in the combinations in which anti-Lyt-2.2 mAb (0) alone
prolonged (A), or did not prolong (B) survival. Anti-L3T4 mAb was injected into recipient
mice on days 0, 4, 14, 21, and 28 in A, and on days 0, 4, and 14 in B. Anti-Lyt-2.2 mAb was
injected on days 0, 4, 14, and 28 in A and on days 0 and 4 in B. O; MEM was injected.
mAb did have an effect. The effect of anti-L3T4 plus anti-Lyt-2.2 mAb in
prolonging survival was augmented by additional injections besides the routine
injections ofboth mAbs (anti-Lyt-2.2 mAb on days 0 and 4; anti-L3T4 mAb on
days 0, 4, and 14).
Serum Antibody Response to Skin Grafts.
￿
Production of serum antibody after
skingrafts was studied byantibody-mediatedcomplement-dependent cytotoxicity
and protein A assays. As shown in Fig. 2, no antibody was detected during an
observation period of 8-11 wk in the serum of B10.A mice with grafted skin
from B10.A(2R), B10.AKM, or B10.BR mice, in the serum of B10.AKM mice
withgrafted skin from B10.A(2R) or B10.BR mice, orin the serum ofB10.A(2R)
mice with grafted skin from B10.BR mice that were treated with medium.
Recipient Injectiondays Graft survival
(mean t SD)
d
B10.A(2R) None 10.7 ± 0.5
0,4 11 .9 ± 1.1
0, 4, 7 11 .8 t 1.1
B10.A None 13.2 ± 2.4
0,4 45.6 t 17.2
0, 4, 14, 28, 42 42.4 ± 11.5c 4096
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FIGURE 4.
￿
Geometric mean titerof H-2 anti-
bodies in BIO.A recipient mice (A) (five mice)
with grafted skin from BIO.A(2R), and in
BIO.A(2R) recipient mice (B) (four mice) with
grafted skin from BIO.A. Antibody production
was determined by protein A assay. Recipient
mice were treated with MEM (0), anti-Lyt-2.2
mAb (0), anti-L3T4 mAb (A), or anti-Lyt-2.2
mAb plus anti-L3T4 mAb(0).
However, antibody was produced in recipient mice in other combinations tested,
and its specificity was shown to be H-2 by testing several B10-congeneic mouse
strains. The results ofcytotoxicity and protein Aassays were essentially the same.
Typical kinetic profiles of antibody production, obtained with B10.A(2R) --*
BIO.A and B10.A --+ B10.A(2R) combinations are shown in Fig. 4. B10.A(2R)
recipient mice treated with both anti-Lyt-2.2 mAb and anti-L3T4 mAb started
to produce antibody right after rejection (see Fig. 3B), indicating that L3T4+
cells with either helper or effector activity had recovered functionally as well as
phenotypically (Fig. 1) by day 30-40.
Discussion
Injection ofanti-Lyt-2.2 mAb into recipient mice prolonged skin graft survival
in 7 of 12 combinations ofH-2D-end difference, but not in 5 other combinations
ofD-end difference, or in 2 combinations of K-end difference. The finding that
anti-Lyt-2.2 mAb prolonged survival ofBIO.A(2R) grafts on BIO.A was consist-
ent with previous reports by others (12). These findings might be explained by
supposing that the positive and negative effects of anti-Lyt-2.2 mAb on graft
survival are simply due to low and high antigenicity, respectively, of allelic H-2
class I antigens. This possibility, however, seems unlikely, because the mean graft
survival times of control mice (treated with MEM) with these various combina-
tions were not significantly different. On the other hand, the effect ofanti-Lyt-
2.2 mAb could be explained on the basis of differential stimulation of effector
T cell populations in response to different H-2 class I antigens. Injection ofanti-
L3T4 mAb had no effect in prolonging graft survival of any combination of
allelic class I differences tested, although it prolonged graft survival in a combi-
nation ofbm12 --* B6 used as a control. Injection of anti-L3T4 mAb together
with anti-Lyt-2.2 mAb markedly prolonged graft survival in combinations in
which anti-Lyt-2.2 mAb had no effect, and enhanced the effect ofanti-Lyt-2.2
mAb in combinations in which anti-Lyt-2.2 mAb had an effect in prolonging
graft survival. These results indicate that, in skin graft ofcombinations in which
anti-Lyt-2.2 mAb had no effect, class I antigens stimulated L3T4' effector cells
when Lyt-2' cells were blocked and Lyt-2' effector cells when L3T4' cells were
blocked. This study did not show whether Lyt-2' or L3T4' cells were the
primary effector cells in these combinations, but the selective stimulation ofLyt-
2' cells in in vitro mixed lymphocyte culture reactions in mouse strains with class988
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I difference (13) suggest that Lyt-2' cells are the primary effectors. Prolongation
of skin graft survival by the injection of both anti-L3T4 mAb and anti-Lyt-2.2
mAb, but not by injection of either alone was also observed with a combination
of H-2 and non-H-2 antigen difference (7). On the other hand, in combinations
in which anti-Lyt-2.2 mAb prolonged graft survival, these antigens preferentially
stimulate Lyt-2' but not L3T' effector cellsinitially,although delayed activation
of L3T' effector cells occurred when Lyt-2' cells were blocked. This was also
the case in the combination bm 1 -+ B6.
In this study, we observed a significant correlation between the effect of anti-
Lyt-2.2 mAb in prolonging graft survival and the failure of recipient mice to
produce H-2 antibody. The finding of no antibody response against several H-
2D antigens was consistent with previous results (14). The fact that injection of
anti-L3T4 mAb abrogated antibody production (15, 16, and this study) indicates
that antibody production was a consequence of activation of L3T4 helper cells.
Therefore, the absence of H-2 antibody production in some combinations of D
difference could have resulted from the absence of stimulation of the L3T4' cell
population. This is consistent with the preferential stimulation of Lyt-2' effector
cells in the initial phase of skin graft rejection in these combinations. However,
exceptions to this rule were observed. In the two combinations B10.A --*
B10.AKM and B10.A(2R) --+ B10.BR, injection of anti-Lyt-2 mAb prolonged
skin graft survival, but H-2 antibody was produced during rejection. On the
other hand, in the combination B10.BR -> BIO.A(2R), anti-Lyt-2.2 mAb had no
effect, but no H-2 antibody was produced. We have no explanation for these
discrepancies at present. It is possible that there are two distinct subsets of
effector and helper cells among L3T4' cells. If so, B10.A and B10.A(2R) skin
may stimulate predominantly L3T4 helper cells but not effector cells in
B10.AKM and B10.BR recipients, respectively, while B10.BR skin may stimulate
L3T4 effector cells but not helper cells in B10.A(2R) recipients. The fact that
injection of anti-L3T4 mAb together with anti-Lyt-2.2 mAb markedly prolonged
survival of grafts in this third combination suggests the presence of L3T4 effector
cells.
Summary
The cellular mechanisms of skin graft rejection with allelic H-2 class I differ-
ences were studied by examining the effect on graft survival of in vivo adminis-
tration of anti-Lyt-2.2 mAb, anti-L3T4 mAb, or both to recipient mice. The
injections of anti-Lyt-2.2 mAb and anti-L3T4 mAb caused selective depletions
of Lyt-2' cells and L3T4' cells, respectively. Injection of anti-Lyt-2.2 mAb
significantly prolonged graft survival in 7 of 12 combinations of H-213-end
difference, but did not prolong graft survival in 5 other combinations of H-2D-
end difference, or in 2 combinations of H-2K-end difference. Injection of anti-
L3T4 mAb did not prolong graft survival in any combinations with class I
difference tested. Injection of anti-L3T4 mAb plus anti-Lyt-2.2 mAb markedly
prolonged graftsurvival in the combinations with class I difference in which anti-
Lyt-2.2 mAb had no effect and overcame the effect of anti-Lyt-2.2 mAb in those
in which anti-Lyt-2.2 mAb had an effect in prolonging graft survival. These
results indicated that in combinations in which anti-Lyt-2.2 mAb did not prolongICHIKAWA ET AL.
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graft survival, class I antigen stimulated L3T4' effector cells when Lyt-2' cells
were blocked and Lyt-2+ effector cells when L3T4' cells were blocked. On the
other hand, in the combinations in which anti-Lyt-2.2 mAb prolong graft
survival, these antigens initially caused preferential stimulation ofLyt-2+ but not
L3T4' effector cells, although delayed activation of L3T4' effector cells oc-
curred when Lyt-2+ cells were blocked. Furthermore, a significant correlation
was found between the effect of anti-Lyt-2.2 mAb in prolonging graft survival
and the failure of recipient mice to produce H-2 antibody. These results can be
taken as evidence that L3T4' effector cells are not involved in the initial phase
ofgraft rejection in these combinations.
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